Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term growth drivers, resulting in a dislocation between price and value.
NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.
![]() 4AB 8 months ago | Other | €1.55 Per Share |
![]() 4AB 11 months ago | Other | €1.55 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Jan 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Oct 2023 | Other | €1.48 Per Share |
23 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | 0.8 EPS |
25 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() 4AB 8 months ago | Other | €1.55 Per Share |
![]() 4AB 11 months ago | Other | €1.55 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Jan 2024 | Other | €1.55 Per Share |
![]() 4AB 12 Oct 2023 | Other | €1.48 Per Share |
23 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | 0.8 EPS |
25 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XETRA Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.